Department of Chemistry, Molecular Design and Synthesis, KU Leuven, Celestijnenlaan 200F - Box 2404, 3001, Leuven, Belgium.
Department of Cellular and Molecular Medicine & Leuven Cancer Institute, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven O&N I, Herestraat 49 - Box 901, 3000, Leuven, Belgium.
ChemMedChem. 2021 Jul 20;16(14):2158-2171. doi: 10.1002/cmdc.202100110. Epub 2021 May 5.
Protein kinase D (PKD) is a serine/threonine kinase family belonging to the Ca2+/calmodulin-dependent protein kinase group. Since its discovery two decades ago, many efforts have been put in elucidating PKD's structure, cellular role and functioning. The PKD family consists of three highly homologous isoforms: PKD1, PKD2 and PKD3. Accumulating cell-signaling research has evidenced that dysregulated PKD plays a crucial role in the pathogenesis of cardiac hypertrophy and several cancer types. These findings led to a broad interest in the design of small-molecule protein kinase D inhibitors. In this review, we present an extensive overview on the past and recent advances in the discovery and development of PKD inhibitors. The focus extends from broad-spectrum kinase inhibitors used in PKD signaling experiments to intentionally developed, bioactive PKD inhibitors. Finally, attention is paid to PKD inhibitors that have been identified as an off-target through large kinome screening panels.
蛋白激酶 D(PKD)是丝氨酸/苏氨酸激酶家族,属于 Ca2+/钙调蛋白依赖性蛋白激酶组。自二十年前发现以来,人们已经投入了大量的努力来阐明 PKD 的结构、细胞作用和功能。PKD 家族由三个高度同源的亚型组成:PKD1、PKD2 和 PKD3。越来越多的细胞信号研究表明,失调的 PKD 在心肌肥厚和几种癌症类型的发病机制中起着关键作用。这些发现导致了人们对设计小分子蛋白激酶 D 抑制剂产生了广泛的兴趣。在这篇综述中,我们全面介绍了 PKD 抑制剂的发现和开发的过去和最新进展。重点从用于 PKD 信号实验的广谱激酶抑制剂扩展到专门开发的、具有生物活性的 PKD 抑制剂。最后,我们还关注了通过大型激酶组筛选面板被鉴定为非靶标的 PKD 抑制剂。